City of Hope Southwest Oncology Group Clinical Trials

描述（由申请人提供）：本提案的总体目标是支持希望之城国家医疗中心（COH）参与西南肿瘤小组（SWOG）的研究性临床试验。COH是nci指定的综合癌症中心，在过去六年中为SWOG的临床研究活动提供了强有力的领导。COH的SWOG成员为血液系统恶性肿瘤的新治疗方案的开发以及干细胞支持的大剂量化疗的各个方面提供了大量的科学投入；此外，肿瘤药理学、细胞遗传学、免疫疗法、泌尿生殖系统癌、妇科病理学和肿瘤生物学方面的专业知识将继续支持SWOG的试点方案开发，并参与全组的II期和III期研究。来自COH的SWOG成员也为肿瘤外科和癌症预防的研究活动做出了重大贡献。在当前的资助周期中，COH的医生和科学家增加了他们在SWOG中的领导活动，增加了泌尿生殖委员会睾丸癌小组委员会和新成立的早期治疗委员会的主席，继续担任骨髓和干细胞移植委员会主席，妇科委员会病理和肿瘤生物学小组委员会主席。除了这些领导职位之外，SWOG内部COH调查员的科学生产力也在不断提高。在上一次对COH参与SWOG的竞争性审查时，9名COH研究者发表了18篇论文和14篇摘要，报告了SWOG的临床研究；在过去的六年里，12名COH研究人员在高质量的同行评审出版物上发表了31篇论文和28篇摘要，描述了SWOG的研究。基于致力于SWOG研究的病理学、外科肿瘤学、放射肿瘤学、癌症控制以及内科肿瘤学、实验治疗学和血液学等多学科医生团队的存在，预计COH在SWOG临床试验方面的实质性科学领导和患者积累将在即将到来的资助周期中继续下去。此外，COH参与SWOG设计的创新治疗概念将扩大南加州地区研究性癌症治疗的可用性。

DESCRIPTION (provided by applicant): The overall objective of this proposal is to support the participation of the City of Hope National Medical Center (COH) in the investigational clinical trials of the Southwest Oncology Group (SWOG). The COH, an NCI-designated Comprehensive Cancer Center, has supplied strong leadership for the clinical research activities of SWOG during the past six years. SWOG members at COH have provided substantial scientific input into the development of new therapeutic programs for hematological malignancies as well as all aspects of high-dose chemotherapy with stem cell support for the group; in addition, expertise in oncologic pharmacology, cytogenetics, immunotherapy, genitourinary cancers, and gynecologic pathology and tumor biology will continue to support pilot protocol development for SWOG as well as participation in group-wide Phase II and Phase III studies. SWOG members from COH also contribute substantially to research activities in oncologic surgery and cancer prevention. COH physicians and scientists have increased their leadership activities within SWOG during the current funding cycle, adding the chairmanships of the Genitourinary Committee's Testis Cancer Subcommittee and the newly formed Early Therapeutics Committee to continuing service as chairs of the Bone Marrow and Stem Cell Transplantation Committee, and the Gynecology Committee's Pathology and Tumor Biology Subcommittees. In addition to these leadership positions, the scientific productivity of COH investigators within SWOG has continued to increase. At the time of the last competitive review of COH's participation in SWOG, 9 COH investigators had published 18 papers and 14 abstracts reporting SWOG clinical investigations; over the past six years, 12 COH investigators have published 31 papers and 28 abstracts describing SWOG research in high-quality, peer-reviewed publications. Based on the presence of a dedicated, multidisciplinary team of physicians in Pathology, Surgical Oncology, Radiation Oncology, and Cancer Control as well as Medical Oncology, Experimental Therapeutics, and Hematology who are committed to the investigations pursued by SWOG, substantive scientific leadership of and patient accrual to SWOG clinical trials by the COH can be predicted to continue over the coming funding cycle. Furthermore, participation by the COH in the innovative treatment concepts devised by SWOG will broaden the availability of investigational cancer care in the greater Southern California region.